Evidence map›Paper›PMID 37069970›Full record

ArticleKidney international reports2023

Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial.

David Z I Cherney, Francesco Cosentino, Darren K McGuire, Ahmed A Kolkailah, Samuel Dagogo-Jack, Richard E Pratley, Robert Frederich, Mario Maldonado, Chih-Chin Liu, Christopher P Cannon and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01986881 (Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01986881 phase3completednot on this map

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2013 to 2019Enrolled8,246ConditionsType 2 Diabetes MellitusArmsErtugliflozin, Placebo, Glycemic Rescue
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 4 countries.

David Z I CherneyDivision of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Francesco CosentinoUnit of Cardiology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
Darren K McGuireDivision of Cardiology, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, USA.
Ahmed A KolkailahDivision of Cardiology, University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, USA.
Samuel Dagogo-JackUniversity of Tennessee Health Science Center, Memphis, Tennessee, USA.
Richard E PratleyAdventHealth Translational Research Institute, Orlando, Florida, USA.
Robert FrederichPfizer Inc., Collegeville, Pennsylvania, USA.
Mario MaldonadoMSD Limited, London, UK.
Chih-Chin LiuMerck & Co., Inc., Rahway, New Jersey, USA.
Christopher P CannonCardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
VERTIS CV Investigators
Parkland Health & Hospital System · USHarvard University · USKarolinska University Hospital · SEMerck & Co., Inc., Rahway, NJ, USA (United States) · USMSD (UK) Limited (United Kingdom) · GBPfizer (United States) · USTranslational Research Institute for Metabolism and Diabetes · USUniversity Health Network · CAUniversity of Tennessee Health Science Center · US

Funding

Training in Cardiovascular ResearchT32HL125247 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI JOSEPH A HILL · 2015 to 2026
$4.3M
NHLBI NIH HHS T32 HL125247
6 · The paper itself

Abstract

Introduction: In the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881), patients with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease (ASCVD) were randomized (1:1:1) to placebo, ertugliflozin 5 mg or 15 mg (doses pooled for analyses as prospectively planned). In this Methods: Baseline HF was defined as a history of HF or prerandomization left ventricular ejection fraction ≤45%. Outcomes included estimated glomerular filtration rate (eGFR) over time, total 5-year eGFR slopes and time to first event of a prespecified exploratory kidney composite outcome of sustained ≥40% decrease from baseline eGFR, chronic kidney replacement therapy, or kidney death. All analyses were stratified by baseline HF status. Results: Compared with no-HF at baseline ( Conclusion: Although patients with HF at baseline had a faster rate of eGFR decline in VERTIS CV, the beneficial effects of ertugliflozin on kidney outcomes did not differ when stratified by baseline HF.

Indexed as

albuminuriadiabetic kidney diseaseertugliflozinheart failuresodium–glucose cotransporter 2 inhibitortype 2 diabetes mellitus

Identifiers

PMID37069970
PMCPMC10105061
OpenAlexW4317623094

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.